<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00094887</url>
  </required_header>
  <id_info>
    <org_study_id>050019, INOT 36</org_study_id>
    <secondary_id>05-H-0019</secondary_id>
    <nct_id>NCT00094887</nct_id>
    <nct_alias>NCT00652535</nct_alias>
  </id_info>
  <brief_title>Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises</brief_title>
  <official_title>A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether nitric oxide (NO) gas can reduce the time it takes for pain
      to go away in patients who are in sickle cell crisis. NO is important in regulating blood
      vessel dilation, and consequently, blood flow. The gas is continuously produced by cells that
      line the blood vessels. It is also transported from the lungs by hemoglobin in red blood
      cells.

      Patients 10 years of age or older with sickle cell disease (known SS, S-beta-thalassemia or
      other blood problems causing sickle cell disease) may be eligible for this study. Patients
      whose disease is due to hemoglobin (Hgb) SC are excluded. Candidates are screened with blood
      tests and a chest x-ray to look at the lungs and heart.

      Participants are admitted to the hospital in a pain crisis. They are evaluated and then
      randomly assigned to receive one of two treatments: 1) standard treatment plus NO, or 2)
      standard treatment plus placebo. The placebo used in this study is nitrogen, a gas that makes
      up most of the air we breathe and is not known to help in sickle cell disease.

      For the first 8 hours of the study, patients receive placebo or NO through a facemask. The
      mask may be taken off for 5 minutes every hour and for not more than 20 minutes to eat a
      meal. After the first 8 hours, the gas is delivered through a nasal cannula (small plastic
      tubing that rests under the nose) that may be taken off only while showering or using the
      restroom. Patients are questioned about the severity of their pain when they start the study
      and then every few hours while they are in the hospital. Their vital signs (temperature,
      breathing rate, and blood pressure) and medicines are checked. Patients will breathe the gas
      for a maximum of 3 days, but will stay hospitalized until the patient feels well enough to go
      home. Patients are followed up about 1 month after starting the study by a return visit to
      the hospital or by a phone call.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The object of this study is to determine the safety and efficacy of nitric oxide for
      inhalation in the treatment of vaso-occlusive pain crisis (VOC) in patients with sickle cell
      disease. The study population will include patients with sickle cell disease (SS,
      S-beta-Thalassemia) presenting with vaso-occlusive pain crisis. Patients will be administered
      either placebo or inhaled nitric oxide to see if the experimental agent, inhaled nitric
      oxide, can reduce the time it takes for resolution of the vaso-occlusive crisis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Resolution of Vaso-occlusive Pain Crisis (VOC)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Time to VOC resolution was defined by:
Pain relief - Visual Analog Scale (VAS) pain scores of 6 or less, (6 as worst and 0 as best) Freedom from parenteral narcotic use, Ability to walk unless the subject was not able to walk for any reason other than acute VOC prior to the onset of crisis, Subject and/or family's belief that the painful crisis could be managed at home with or without oral analgesic use, and the physician concurred with that assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>At baseline, then every hour for the first 8 hours of therapy, followed by every 4 hours of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methemoglobin Levels</measure>
    <time_frame>at 2,4,6, and 8 hours after the start of therapy and then every 24 hours while on therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Analgesics</measure>
    <time_frame>baseline and throughout treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Levels</measure>
    <time_frame>every 24 hours for the first 5 days after start of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospitalization From Admissions Defined by the Time of the Discharge Order is Written</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Acute Chest Syndrome/Pneumonia Requiring Blood Transfusion</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Anemia, Sickle Cell</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled nitric oxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nitrogen gas</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>INOmax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Nitrogen gas will be delivered in the same manor as the experimental drug.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each subject must meet all of the following inclusion criteria during the screening process
        in order to participate in the study:

          -  Patient must have a diagnosis of SCD (known SS, S-Beta-thalassemia or other
             hemoglobinopathies causing sickle cell disease). Patients with disease due to Hgb SC
             are not permitted.

          -  Must present to the ED/EC or other appropriate unit in VOC.

          -  Greater than or equal to 10 years old.

          -  Written informed consent/assent has been obtained.

        Exclusion Criteria:

        Subjects meeting any of the following criteria during baseline evaluation will be excluded
        from entry into the study:

          -  Exposure to therapeutic nitric oxide within the past 12 hours.

          -  Patient has received sildenafil or other phosphodiesterase 5 inhibitors, therapeutic
             L-arginine, nitroprusside or nitroglycerine within the past 12 hours.

          -  Patient has received previous ED/EC or other appropriate unit treatment for a
             vaso-occlusive crisis less than 48 hours or hospitalization less than 14 days ago
             (patients transferred directly from another ED or clinic may be enrolled).

          -  Patient has visited the ED/EC or other appropriate unit greater than 10 times in the
             past year having a vaso-occlusive crisis.

          -  Patients presenting with clinically diagnosed bacterial infection (e.g.,
             osteomyelitis, pneumonia, sepsis or meningitis).

          -  Patients who are currently enrolled in any other investigational drug study except for
             hydroxyurea studies.

          -  Pregnant women (urine HCG + )/ nursing mothers.

          -  Patients who have received an exchange transfusion (not simple transfusion) in the
             last 30 days or are on a chronic simple or exchange transfusion program.

          -  Suspected splenic sequestration.

          -  Acute chest syndrome or pneumonia: Abnormal new pulmonary infiltrate (alveolar
             infiltration and not atelectasis) and one or more pulmonary signs and/or symptoms
             (fever, rales, wheezing, cough, shortness of breath, retractions).

          -  Previous participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Baldassarre, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609-1809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Sickle Cell Treatement and Research Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard University Hospital</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital, Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-2602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital, Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2583</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/m/pubmed/1302470/</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Sanders DY, Severance HW, Pollack CV Jr. Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department. South Med J. 1992 Aug;85(8):808-11.</citation>
    <PMID>1302470</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2004</study_first_submitted>
  <study_first_submitted_qc>October 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2004</study_first_posted>
  <results_first_submitted>December 4, 2009</results_first_submitted>
  <results_first_submitted_qc>April 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2010</results_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Flow</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Pain Crisis</keyword>
  <keyword>Sickle Cell Anemia</keyword>
  <keyword>Vaso-Occlusive Crisis</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>SCD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Multicenter; 11 study centers enrolled subjects Date first subject enrolled: 13 April, 2005 Date last subject completed: 15 December, 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Nitric Oxide</title>
          <description>Inhaled Nitric Oxide INO</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Nitrogen gas</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75">75</participants>
                <participants group_id="P2" count="75">75</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Family emergency, Subject noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Nitric Oxide</title>
          <description>Inhaled Nitric Oxide INO</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Nitrogen gas</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 16 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=16 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="11.06"/>
                    <measurement group_id="B2" value="26.0" spread="10.49"/>
                    <measurement group_id="B3" value="26.3" spread="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Resolution of Vaso-occlusive Pain Crisis (VOC)</title>
        <description>Time to VOC resolution was defined by:
Pain relief - Visual Analog Scale (VAS) pain scores of 6 or less, (6 as worst and 0 as best) Freedom from parenteral narcotic use, Ability to walk unless the subject was not able to walk for any reason other than acute VOC prior to the onset of crisis, Subject and/or family’s belief that the painful crisis could be managed at home with or without oral analgesic use, and the physician concurred with that assessment.</description>
        <time_frame>Up to 30 days</time_frame>
        <population>75 subjects were assigned to treatment with iNO and 75 subjects were assigned to treatment with placebo; all subjects were included in the ITT and Safety Populations. 142 subjects completed the study according to the protocol and 8 subjects (4 in each treatment group) did not complete the study according to protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled Nitric Oxide INO</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Nitrogen gas</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Vaso-occlusive Pain Crisis (VOC)</title>
          <description>Time to VOC resolution was defined by:
Pain relief - Visual Analog Scale (VAS) pain scores of 6 or less, (6 as worst and 0 as best) Freedom from parenteral narcotic use, Ability to walk unless the subject was not able to walk for any reason other than acute VOC prior to the onset of crisis, Subject and/or family’s belief that the painful crisis could be managed at home with or without oral analgesic use, and the physician concurred with that assessment.</description>
          <population>75 subjects were assigned to treatment with iNO and 75 subjects were assigned to treatment with placebo; all subjects were included in the ITT and Safety Populations. 142 subjects completed the study according to the protocol and 8 subjects (4 in each treatment group) did not complete the study according to protocol.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.83" lower_limit="41.75" upper_limit="78.00"/>
                    <measurement group_id="O2" value="55.16" lower_limit="46.00" upper_limit="72.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs</title>
        <time_frame>At baseline, then every hour for the first 8 hours of therapy, followed by every 4 hours of therapy.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methemoglobin Levels</title>
        <time_frame>at 2,4,6, and 8 hours after the start of therapy and then every 24 hours while on therapy.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Analgesics</title>
        <time_frame>baseline and throughout treatment.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Chemistry Levels</title>
        <time_frame>every 24 hours for the first 5 days after start of treatment.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospitalization From Admissions Defined by the Time of the Discharge Order is Written</title>
        <time_frame>study duration</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Acute Chest Syndrome/Pneumonia Requiring Blood Transfusion</title>
        <time_frame>study duration</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>75 subjects were assigned to treatment with iNO and 75 subjects were assigned to treatment with placebo; all subjects were included in the ITT and Safety Populations. 142 subjects completed the study according to the protocol and 8 subjects (4 in each treatment group) did not complete the study according to protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Nitric Oxide</title>
          <description>Inhaled Nitric Oxide INO</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Nitrogen gas</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (7.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 7.0">Acute Chest Syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sensation of Foreign Body</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin Decrease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA (7.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lawrence Hill</name_or_title>
      <organization>Mallinckrodt Pharmaceuticals</organization>
      <phone>908-238-6370</phone>
      <email>lawrence.hill@mallinckrodt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

